Based on the Sophia Genetics SA stock forecast from 3 analysts, the average analyst target price for Sophia Genetics SA is USD 7.67 over the next 12 months. Sophia Genetics SA’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Sophia Genetics SA is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Sophia Genetics SA’s stock price was USD 3.11. Sophia Genetics SA’s stock price has changed by +4.05% over the past week, +10.68% over the past month and -32.97% over the last year.
No recent analyst target price found for Sophia Genetics SA
No recent average analyst rating found for Sophia Genetics SA
Company Overview Sophia Genetics SA
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is based in Rolle, Switzerland. Read Less
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platfo...Read More
Frequently Asked Questions About Sophia Genetics SA (SOPH) Stock
Based on ratings from 3 analysts Sophia Genetics SA's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 2 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on SOPH's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for SOPH is USD 7.67 over the next 12 months. The maximum analyst target price is USD 11 while the minimum anlayst target price is USD 5.
SOPH stock's Price/Earning ratio is 464.52.
Our analysis grades SOPH stock's Price / Earning ratio at F. This means that SOPH stock's Price/Earning ratio is above 92% of the stocks in the Health Information Services sector in the NSD exchange.
Based on this SOPH may be a overvalued for its sector.
The last closing price of SOPH's stock was USD 3.11.
The most recent market capitalization for SOPH is USD 0.19B.
Based on targets from 3 analysts, the average taret price for SOPH is projected at USD 7.67 over the next 12 months.
This means that SOPH's stock price may go up by +146.52% over the next 12 months.
We can't find any ETFs which contains Sophia Genetics SA's stock.
As per our most recent records Sophia Genetics SA has 423 Employees.
Sophia Genetics SA's registered address is La Pièce 12, Rolle, Switzerland, 1180.
You can get more information about it from Sophia Genetics SA's website at https://www.sophiagenetics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Sophia Genetics SA (SOPH) Stock
Based on ratings from 3 analysts Sophia Genetics SA's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 2 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on SOPH's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for SOPH is USD 7.67 over the next 12 months. The maximum analyst target price is USD 11 while the minimum anlayst target price is USD 5.
SOPH stock's Price/Earning ratio is 464.52.
Our analysis grades SOPH stock's Price / Earning ratio at F. This means that SOPH stock's Price/Earning ratio is above 92% of the stocks in the Health Information Services sector in the NSD exchange.
Based on this SOPH may be a overvalued for its sector.
The last closing price of SOPH's stock was USD 3.11.
The most recent market capitalization for SOPH is USD 0.19B.
Based on targets from 3 analysts, the average taret price for SOPH is projected at USD 7.67 over the next 12 months.
This means that SOPH's stock price may go up by +146.52% over the next 12 months.
We can't find any ETFs which contains Sophia Genetics SA's stock.
As per our most recent records Sophia Genetics SA has 423 Employees.
Sophia Genetics SA's registered address is La Pièce 12, Rolle, Switzerland, 1180.
You can get more information about it from Sophia Genetics SA's website at https://www.sophiagenetics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SOPH !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
